Similar articles

• Evaluation of vigabatrin as an add-on drug in the management of severe epilepsy.

  Sander JW, Trevisol-Bittencourt PC, Hart YM, Shorvon SD. Sander JW, et al. J Neurol Neurosurg Psychiatry. 1990 Nov;53(11):1008-10. doi: 10.1136/jnnp.53.11.1008. J Neurol Neurosurg Psychiatry. 1990. PMID: 2283513 Free PMC article. Clinical Trial.
• Complex partial status after starting vigabatrin.

  Rogers D, Bird J, Eames P. Rogers D, et al. Seizure. 1993 Jun;2(2):155-6. doi: 10.1016/s1059-1311(05)80122-0. Seizure. 1993. PMID: 8167969 No abstract available.
• Vigabatrin in epilepsy in mentally retarded patients.

  Matilainen R, Pitkänen A, Ruutiainen T, Mervaala E, Riekkinen P. Matilainen R, et al. Br J Clin Pharmacol. 1989;27 Suppl 1(Suppl 1):113S-118S. doi: 10.1111/j.1365-2125.1989.tb03471.x. Br J Clin Pharmacol. 1989. PMID: 2757902 Free PMC article.
• Vigabatrin.

  [No authors listed] [No authors listed] Lancet. 1989 Mar 11;1(8637):532-3. Lancet. 1989. PMID: 2564063 Review. No abstract available.
• Vigabatrin. Clinical pharmacokinetics.

  Rey E, Pons G, Olive G. Rey E, et al. Clin Pharmacokinet. 1992 Oct;23(4):267-78. doi: 10.2165/00003088-199223040-00003. Clin Pharmacokinet. 1992. PMID: 1395360 Review.